The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1523
Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
The full article is available to subscribers Subscriber Login   

The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran (Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with ultraviolet A (UVA) light (KXL System) in the corneal collagen cross-linking treatment of two corneal disorders: progressive keratoconus and corneal ectasia following refractive surgery. It is the first corneal collagen cross-linking (CXL) treatment to be approved by the FDA.

THE DISORDERS — Keratoconus is a noninflammatory corneal thinning disorder with an incidence of about 1 in 1750. It usually presents in adolescence and progresses for one to two decades.1 The disorder has a variable presentation, ranging from myopic astigmatism requiring only spectacle correction to significant corneal stromal thinning, cone-like protrusion of the cornea, and corneal ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
Article code: 1523e
 Electronic, downloadable article - $25